Depression in Patients with Nonalcoholic Fatty Liver Disease and Chronic Viral Hepatitis B and C

Weinstein, Ali A.; Price, Jillian Kallman; Stepanova, Maria; Poms, Laura Wheeler; Fang, Yun; Moon, Juhi; Nader, Fatema; Younossi, Zobair M.

doi:10.1016/j.psym.2010.12.019

Cited by 123 publications

(123 citation statements)

References 20 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…39 However, these patients do experience an increased rate of adverse psychological effects. Noncirrhotic chronic HBV patients who completed SF-36 questionnaires demonstrated significant reductions in their scores for 'mental health' and 'general health perception' compared to healthy controls.…”

Section: Hepatitis Bmentioning

confidence: 99%

“…Non-alcoholic fatty liver disease Depressive symptoms occur in at least one-quarter of patients with NAFLD, 28,39 but the evidence is contradictory as to whether NAFLD is an independent risk factor for depression, with some data sets supporting this, 46 while others do not. 28 A recent cross-sectional study assessed a cohort of 567 North American patients with biopsy-proven NA-FLD, including patients with the entire spectrum of the condition (i.e.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Mullish

Kabir

Thursz

et al. 2014

Aliment Pharmacol Ther

115

View full text Add to dashboard Cite

SummaryBackgroundThe scale of depression in patients with chronic liver disease (CLD) and those who have received orthotopic liver transplantation (OLT) is poorly characterised. Clinicians are uncertain of how best to manage depression within these patients.AimsTo review the literature evaluating both the prevalence and impact of depression in patients with CLD and post‐OLT, and to assess the safety and efficacy of antidepressant use within this context.MethodsA PubMed search using the phrases ‘chronic liver disease’, ‘cirrhosis’, ‘liver transplantation’, ‘depression’, ‘antidepressant’ and the names of specific causes of liver disease and individual antidepressants.ResultsOver 30% of cirrhotic patients have depressive features, and they experience worse clinical outcomes than nondepressed cirrhotic patients. CLD patients with chronic hepatitis C are particularly prone to depression, partly related to the use of interferon therapy. OLT patients with depression have higher mortality rates than nondepressed patients; appropriate antidepressant use reverses this effect. Selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) are effective and generally safe in both CLD and OLT patients.ConclusionsDepression is much more prevalent in CLD or OLT patients than is generally recognised, and it adversely affects clinical outcomes. The reasons for this relationship are complex and multifactorial. Antidepressants are effective in both CLD and post‐OLT, although lower doses or a reduced dosing frequency may be required to minimise side effects, e.g. exacerbation of hepatic encephalopathy. Further research is needed to establish optimal management of depression in these patients, including the potential role of nonpharmacological treatments.

show abstract

Section: Hepatitis Bmentioning

confidence: 99%

mentioning

confidence: 99%

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Mullish

Kabir

Thursz

et al. 2014

Aliment Pharmacol Ther

115

View full text Add to dashboard Cite

show abstract

“…Most of the previous studies have been focused on depression in CLD 4,6,7,12,[14][15][16][17] , while only a few have been devoted to anxiety in these patients 6,14,16,17 . Published studies data were heterogenic, both in terms of study population, different diagnostic criteria and assessment instruments that were used for the diagnosis of depression and anxiety.…”

Section: Introductionmentioning

confidence: 99%

Assessment of depression and anxiety in patients with chronic liver disease

Popović¹,

Culafic²,

Kisić-Tepavčević³

et al. 2015

VSP

View full text Add to dashboard Cite

show abstract

“…The decrease in HR-QOL may also be affected by the significant and complex interplay between obesity and its associated psychological and psychiatric issues of [43][44][45]. To date, most studies of HR-QOL in NAFLD exclude patients with underlying psychiatric issues so the true impact of these co-morbidities on NAFLD patients' HR-QOL cannot be fully assessed.…”

Section: Nafld and Health-related Quality Of Lifementioning

confidence: 99%

Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease

Younossi

Henry

2015

PharmacoEconomics

Self Cite

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a very common chronic liver disease worldwide, is on the rise following the trend of increasing prevalence of obesity, is the second most common indication for liver transplantation, and is an important cause for hepatocellular carcinoma. Despite the increasing recognition of NAFLD as an important chronic liver disease, little has been published on the economic and health-related quality of life (HR-QOL) impact of NAFLD. We reviewed the current literature related to the economics and HR-QOL of NAFLD and found that increased costs and decreased HR-QOL were associated with NAFLD.

show abstract

Depression in Patients with Nonalcoholic Fatty Liver Disease and Chronic Viral Hepatitis B and C

Cited by 123 publications

References 20 publications

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Assessment of depression and anxiety in patients with chronic liver disease

Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About